Clinical effect of dipeptide base Ⅳ peptide enzyme inhibitors combined with insulin in the treatment of type 2 diabetes
10.3760/cma.j.issn.1008-6706.2017.14.020
- VernacularTitle:二肽基肽酶Ⅳ抑制剂联合胰岛素对2型糖尿病的临床疗效
- Author:
Yanxia WANG
- Keywords:
Diabetes;
type 2;
DPP-4 inhibitors;
Blood glucose
- From:
Chinese Journal of Primary Medicine and Pharmacy
2017;24(14):2151-2155
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the clinical curative effect of dipeptide base peptidase Ⅳ inhibitors (DPP-4) combined with insulin in the treatment of type 2 diabetes.Methods 100 patients with type 2 diabetes were selected as the research subjects,and they were randomly divided into two groups by single blind randomization method,50 cases in each group.The control group adopted the premixed insulin therapy for a month,the observation group received the DPP-4 inhibitors combined with premixed insulin therapy for a month.The blood sugar success rate,weight,incidence of hypoglycemia of the two groups were compared.Results After treatment,the fasting blood glucose value,2 h postprandial blood glucose of the two groups were significantly decreased(t=5.155,P=0.000;t=6.591,P=0.000;t=7.488,P=0.000;t=7.574,P=0.000).But there were no statistical differences between the two groups after treatment (all P>0.05).The incidence rate of hypoglycemic events of the observation group was obviously lower than that of the control group (x2=5.982,P=5.982).Before treatment,the ALT,AST,serum creatinine,urea nitrogen between the two groups had no significant differences(all P>0.05).The body weight,body mass index of the observation group were significantly lower than those of the control group (t=6.931,P=0.000;t=16.010,P=0.000).Conclusion The DPP-4 inhibitor combined premixed insulin therapy for type 2 diabetes has significant hypoglycemic effect,can effectively reduce hypoglycemic events,effectively control the weight,and its effect on liver and kidney function is relatively mild,safe and reliable.
